JP6192830B2 - 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 - Google Patents

抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 Download PDF

Info

Publication number
JP6192830B2
JP6192830B2 JP2016528540A JP2016528540A JP6192830B2 JP 6192830 B2 JP6192830 B2 JP 6192830B2 JP 2016528540 A JP2016528540 A JP 2016528540A JP 2016528540 A JP2016528540 A JP 2016528540A JP 6192830 B2 JP6192830 B2 JP 6192830B2
Authority
JP
Japan
Prior art keywords
flecainide
disorder
modafinil
sleep
narcolepsy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016528540A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525140A5 (enExample
JP2016525140A (ja
Inventor
ムートン，フランク
シャルヴリア，マチュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Publication of JP2016525140A publication Critical patent/JP2016525140A/ja
Publication of JP2016525140A5 publication Critical patent/JP2016525140A5/ja
Application granted granted Critical
Publication of JP6192830B2 publication Critical patent/JP6192830B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Virology (AREA)
JP2016528540A 2013-07-24 2014-07-24 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 Expired - Fee Related JP6192830B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306074 2013-07-24
EP13306074.9 2013-07-24
PCT/EP2014/065975 WO2015011246A1 (en) 2013-07-24 2014-07-24 Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017061022A Division JP6453931B2 (ja) 2013-07-24 2017-03-27 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法

Publications (3)

Publication Number Publication Date
JP2016525140A JP2016525140A (ja) 2016-08-22
JP2016525140A5 JP2016525140A5 (enExample) 2016-12-15
JP6192830B2 true JP6192830B2 (ja) 2017-09-06

Family

ID=48900920

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016528540A Expired - Fee Related JP6192830B2 (ja) 2013-07-24 2014-07-24 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法
JP2017061022A Expired - Fee Related JP6453931B2 (ja) 2013-07-24 2017-03-27 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法
JP2018233114A Expired - Fee Related JP6694497B2 (ja) 2013-07-24 2018-12-13 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017061022A Expired - Fee Related JP6453931B2 (ja) 2013-07-24 2017-03-27 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法
JP2018233114A Expired - Fee Related JP6694497B2 (ja) 2013-07-24 2018-12-13 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法

Country Status (20)

Country Link
US (3) US9750734B2 (enExample)
EP (2) EP3308785A3 (enExample)
JP (3) JP6192830B2 (enExample)
KR (2) KR20170068629A (enExample)
CN (1) CN105579041B (enExample)
AU (1) AU2014295030B2 (enExample)
BR (1) BR112016001446A8 (enExample)
CA (2) CA2919140C (enExample)
DK (1) DK3024458T3 (enExample)
ES (1) ES2661647T3 (enExample)
HR (1) HRP20180487T1 (enExample)
HU (1) HUE037122T2 (enExample)
IL (2) IL243746A (enExample)
MX (2) MX365782B (enExample)
PL (1) PL3024458T3 (enExample)
PT (1) PT3024458T (enExample)
RU (2) RU2661026C2 (enExample)
TR (1) TR201802302T4 (enExample)
WO (1) WO2015011246A1 (enExample)
ZA (1) ZA201601146B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017009472A1 (en) * 2015-07-15 2017-01-19 Theranexus Use of amitriptyline for blocking brain hemichannels and method for potentiating its effect in vivo
WO2019183470A2 (en) 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
EP3781128A4 (en) * 2018-04-16 2022-03-09 Alsar Ltd Partnership COMPOSITIONS AND METHODS FOR THE EXTENDED RELEASE OF FLECAINIDE
US12529704B2 (en) 2018-06-11 2026-01-20 Indiana University Research And Technology Corporation Methods for objective assessment of stress, early detection of risk for stress disorders, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
EP3593822A1 (en) 2018-07-13 2020-01-15 Theranexus Therapeutic and diagnostic applications of a new method of monitoring of neuroglial interaction memri)
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11021410B2 (en) * 2018-12-10 2021-06-01 Purdue Research Foundation Layer-wise agglomerated urea granules
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US20220265666A1 (en) * 2019-08-02 2022-08-25 Praxis Precision Medicines, Inc. Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and adolescent depression
CN111018694A (zh) * 2019-12-12 2020-04-17 贵州省欣紫鸿药用辅料有限公司 一种氟卡尼的生产方法
AU2021270308A1 (en) * 2020-05-13 2022-12-15 Akouos, Inc. Compositions and methods for treating GJB2-associated hearing loss
KR102390194B1 (ko) * 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
WO2022170081A1 (en) * 2021-02-05 2022-08-11 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001253825A (ja) 2000-03-13 2001-09-18 Masahiko Ichimada 帯状疱疹後神経痛用鎮痛剤
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
AU2006318447A1 (en) 2005-11-21 2007-05-31 The Board Of Trustees Of The University Of Alabama For And On Behalf Of The University Of Alabama Methods of using small molecule compounds for neuroprotection
KR20100027091A (ko) * 2006-11-15 2010-03-10 코다 테라퓨틱스, 인크. 상처 치유를 위한 개선 방법 및 조성물
FR2935611B1 (fr) * 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
US20130184462A1 (en) 2010-09-30 2013-07-18 Council Of Scientific & Industrial Research Method for predicting and modeling anti-psychotic activity using virtual screening model
US20130096067A1 (en) 2011-09-14 2013-04-18 Norbert Perrimon Drosophila tumor stem cell model and uses thereof
EP2586436A1 (en) * 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor

Also Published As

Publication number Publication date
PL3024458T3 (pl) 2018-08-31
KR101754045B1 (ko) 2017-07-05
RU2016105971A (ru) 2017-08-25
CN105579041B (zh) 2019-04-19
US20180028519A1 (en) 2018-02-01
US20160158213A1 (en) 2016-06-09
IL254210A0 (en) 2017-10-31
TR201802302T4 (tr) 2018-03-21
DK3024458T3 (en) 2018-02-19
HUE037122T2 (hu) 2018-08-28
PT3024458T (pt) 2018-04-11
JP6694497B2 (ja) 2020-05-13
CA2997282A1 (en) 2015-01-29
EP3308785A2 (en) 2018-04-18
IL243746A0 (en) 2016-04-21
RU2018122564A (ru) 2019-03-06
US10639301B2 (en) 2020-05-05
ES2661647T3 (es) 2018-04-02
CA2919140C (en) 2018-05-01
US20190008844A1 (en) 2019-01-10
BR112016001446A2 (pt) 2017-08-29
MX2019006878A (es) 2019-08-01
ZA201601146B (en) 2017-11-29
WO2015011246A1 (en) 2015-01-29
JP2017119710A (ja) 2017-07-06
EP3024458B1 (en) 2018-01-03
IL254210B (en) 2021-10-31
EP3024458A1 (en) 2016-06-01
IL243746A (en) 2017-09-28
KR20170068629A (ko) 2017-06-19
CA2919140A1 (en) 2015-01-29
BR112016001446A8 (pt) 2018-01-23
RU2661026C2 (ru) 2018-07-11
HRP20180487T1 (hr) 2018-05-04
EP3308785A3 (en) 2018-07-18
JP2016525140A (ja) 2016-08-22
KR20160058760A (ko) 2016-05-25
MX2016001049A (es) 2016-08-12
CN105579041A (zh) 2016-05-11
MX365782B (es) 2019-06-13
JP2019059773A (ja) 2019-04-18
US9750734B2 (en) 2017-09-05
JP6453931B2 (ja) 2019-01-16
AU2014295030B2 (en) 2017-06-01
AU2014295030A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
JP6453931B2 (ja) 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法
JP2016525140A5 (enExample)
EP4366729A2 (en) Safer psychoactive compositions
Renner et al. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine
US20220296584A1 (en) Membrane Active Molecules
TWI787260B (zh) 具有新穎的組成物、組合物及其方法之標靶藥物救援
JP2011511845A (ja) アルファ７（α７）ニコチン作動薬と抗精神病薬との組合せ物
US20200261442A1 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
JP2017132802A (ja) ヒストンアセチルトランスフェラーゼ活性剤の使用
CN102395358A (zh) Nk受体拮抗剂的用途
US9526721B2 (en) Tetrahydroprotoberbine compounds and uses thereof in the treatment of neurological, psychiatric and neurodegenerative diseases
US20170290823A1 (en) Method of treating parkinson's disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity
HK1225278A1 (en) Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug
HK1225278B (en) Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug
CN115925628B (zh) 青藤碱酯类衍生物及其制备方法和应用、镇痛药物
Zare et al. Wake-Promoting agents; insights into clinical use and molecular perspectives
EP2891491A1 (en) Use of (r)-phenylpiracetam for the treatment of sleep disorders
Crawford through changes in the level of free serotonin. Reserpine, by preventing tissue binding of this biogenic amine, may produce a higher than normal content of free serotonin. The serotoninergic

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160616

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20160616

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20160720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160726

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20161026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161027

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170327

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170626

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170808

R150 Certificate of patent or registration of utility model

Ref document number: 6192830

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees